The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hematologic Malignancies-Global Market Insights and Sales Trends 2025
Synopsis
The global Hematologic Malignancies market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hematologic Malignancies in various end use industries. The expanding demands from the Chemotherapy, Radiotherapy, Immunotherapy and Stem Cell Transplantation, are propelling Hematologic Malignancies market. Leukemia, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Lymphoma segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hematologic Malignancies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hematologic Malignancies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hematologic Malignancies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hematologic Malignancies sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hematologic Malignancies covered in this report include Pfizer, Inc., F. Hoffmann-LA Roche ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation and Johnson & Johnson Services, Inc., etc.
The global Hematologic Malignancies market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer, Inc.
F. Hoffmann-LA Roche ltd
Sanofi-Aventis
Bristol-Myers Squibb Company
AbbVie, Inc.
Novartis AG
GlaxoSmithKline PLC
Celgene Corporation
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company limited
Global Hematologic Malignancies market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hematologic Malignancies market, Segment by Type:
Leukemia
Lymphoma
Multiple Myeloma
Others
Global Hematologic Malignancies market, by Application
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hematologic Malignancies companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Hematologic Malignancies market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hematologic Malignancies in various end use industries. The expanding demands from the Chemotherapy, Radiotherapy, Immunotherapy and Stem Cell Transplantation, are propelling Hematologic Malignancies market. Leukemia, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Lymphoma segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hematologic Malignancies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hematologic Malignancies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hematologic Malignancies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hematologic Malignancies sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hematologic Malignancies covered in this report include Pfizer, Inc., F. Hoffmann-LA Roche ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation and Johnson & Johnson Services, Inc., etc.
The global Hematologic Malignancies market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer, Inc.
F. Hoffmann-LA Roche ltd
Sanofi-Aventis
Bristol-Myers Squibb Company
AbbVie, Inc.
Novartis AG
GlaxoSmithKline PLC
Celgene Corporation
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company limited
Global Hematologic Malignancies market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hematologic Malignancies market, Segment by Type:
Leukemia
Lymphoma
Multiple Myeloma
Others
Global Hematologic Malignancies market, by Application
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hematologic Malignancies companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hematologic Malignancies
1.1 Hematologic Malignancies Market Overview
1.1.1 Hematologic Malignancies Product Scope
1.1.2 Hematologic Malignancies Market Status and Outlook
1.2 Global Hematologic Malignancies Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hematologic Malignancies Market Size by Region (2018-2029)
1.4 Global Hematologic Malignancies Historic Market Size by Region (2018-2023)
1.5 Global Hematologic Malignancies Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hematologic Malignancies Market Size (2018-2029)
1.6.1 North America Hematologic Malignancies Market Size (2018-2029)
1.6.2 Europe Hematologic Malignancies Market Size (2018-2029)
1.6.3 Asia-Pacific Hematologic Malignancies Market Size (2018-2029)
1.6.4 Latin America Hematologic Malignancies Market Size (2018-2029)
1.6.5 Middle East & Africa Hematologic Malignancies Market Size (2018-2029)
2 Hematologic Malignancies Market by Type
2.1 Introduction
2.1.1 Leukemia
2.1.2 Lymphoma
2.1.3 Multiple Myeloma
2.1.4 Others
2.2 Global Hematologic Malignancies Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hematologic Malignancies Historic Market Size by Type (2018-2023)
2.2.2 Global Hematologic Malignancies Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hematologic Malignancies Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hematologic Malignancies Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hematologic Malignancies Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hematologic Malignancies Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hematologic Malignancies Revenue Breakdown by Type (2018-2029)
3 Hematologic Malignancies Market Overview by Application
3.1 Introduction
3.1.1 Chemotherapy
3.1.2 Radiotherapy
3.1.3 Immunotherapy
3.1.4 Stem Cell Transplantation
3.1.5 Others
3.2 Global Hematologic Malignancies Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hematologic Malignancies Historic Market Size by Application (2018-2023)
3.2.2 Global Hematologic Malignancies Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hematologic Malignancies Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hematologic Malignancies Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hematologic Malignancies Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hematologic Malignancies Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hematologic Malignancies Revenue Breakdown by Application (2018-2029)
4 Hematologic Malignancies Competition Analysis by Players
4.1 Global Hematologic Malignancies Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hematologic Malignancies as of 2022)
4.3 Date of Key Players Enter into Hematologic Malignancies Market
4.4 Global Top Players Hematologic Malignancies Headquarters and Area Served
4.5 Key Players Hematologic Malignancies Product Solution and Service
4.6 Competitive Status
4.6.1 Hematologic Malignancies Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer, Inc.
5.1.1 Pfizer, Inc. Profile
5.1.2 Pfizer, Inc. Main Business
5.1.3 Pfizer, Inc. Hematologic Malignancies Products, Services and Solutions
5.1.4 Pfizer, Inc. Hematologic Malignancies Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer, Inc. Recent Developments
5.2 F. Hoffmann-LA Roche ltd
5.2.1 F. Hoffmann-LA Roche ltd Profile
5.2.2 F. Hoffmann-LA Roche ltd Main Business
5.2.3 F. Hoffmann-LA Roche ltd Hematologic Malignancies Products, Services and Solutions
5.2.4 F. Hoffmann-LA Roche ltd Hematologic Malignancies Revenue (US$ Million) & (2018-2023)
5.2.5 F. Hoffmann-LA Roche ltd Recent Developments
5.3 Sanofi-Aventis
5.3.1 Sanofi-Aventis Profile
5.3.2 Sanofi-Aventis Main Business
5.3.3 Sanofi-Aventis Hematologic Malignancies Products, Services and Solutions
5.3.4 Sanofi-Aventis Hematologic Malignancies Revenue (US$ Million) & (2018-2023)
5.3.5 Bristol-Myers Squibb Company Recent Developments
5.4 Bristol-Myers Squibb Company
5.4.1 Bristol-Myers Squibb Company Profile
5.4.2 Bristol-Myers Squibb Company Main Business
5.4.3 Bristol-Myers Squibb Company Hematologic Malignancies Products, Services and Solutions
5.4.4 Bristol-Myers Squibb Company Hematologic Malignancies Revenue (US$ Million) & (2018-2023)
5.4.5 Bristol-Myers Squibb Company Recent Developments
5.5 AbbVie, Inc.
5.5.1 AbbVie, Inc. Profile
5.5.2 AbbVie, Inc. Main Business
5.5.3 AbbVie, Inc. Hematologic Malignancies Products, Services and Solutions
5.5.4 AbbVie, Inc. Hematologic Malignancies Revenue (US$ Million) & (2018-2023)
5.5.5 AbbVie, Inc. Recent Developments
5.6 Novartis AG
5.6.1 Novartis AG Profile
5.6.2 Novartis AG Main Business
5.6.3 Novartis AG Hematologic Malignancies Products, Services and Solutions
5.6.4 Novartis AG Hematologic Malignancies Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis AG Recent Developments
5.7 GlaxoSmithKline PLC
5.7.1 GlaxoSmithKline PLC Profile
5.7.2 GlaxoSmithKline PLC Main Business
5.7.3 GlaxoSmithKline PLC Hematologic Malignancies Products, Services and Solutions
5.7.4 GlaxoSmithKline PLC Hematologic Malignancies Revenue (US$ Million) & (2018-2023)
5.7.5 GlaxoSmithKline PLC Recent Developments
5.8 Celgene Corporation
5.8.1 Celgene Corporation Profile
5.8.2 Celgene Corporation Main Business
5.8.3 Celgene Corporation Hematologic Malignancies Products, Services and Solutions
5.8.4 Celgene Corporation Hematologic Malignancies Revenue (US$ Million) & (2018-2023)
5.8.5 Celgene Corporation Recent Developments
5.9 Johnson & Johnson Services, Inc.
5.9.1 Johnson & Johnson Services, Inc. Profile
5.9.2 Johnson & Johnson Services, Inc. Main Business
5.9.3 Johnson & Johnson Services, Inc. Hematologic Malignancies Products, Services and Solutions
5.9.4 Johnson & Johnson Services, Inc. Hematologic Malignancies Revenue (US$ Million) & (2018-2023)
5.9.5 Johnson & Johnson Services, Inc. Recent Developments
5.10 Takeda Pharmaceutical Company limited
5.10.1 Takeda Pharmaceutical Company limited Profile
5.10.2 Takeda Pharmaceutical Company limited Main Business
5.10.3 Takeda Pharmaceutical Company limited Hematologic Malignancies Products, Services and Solutions
5.10.4 Takeda Pharmaceutical Company limited Hematologic Malignancies Revenue (US$ Million) & (2018-2023)
5.10.5 Takeda Pharmaceutical Company limited Recent Developments
6 North America
6.1 North America Hematologic Malignancies Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Hematologic Malignancies Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hematologic Malignancies Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hematologic Malignancies Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hematologic Malignancies Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hematologic Malignancies Market Dynamics
11.1 Hematologic Malignancies Industry Trends
11.2 Hematologic Malignancies Market Drivers
11.3 Hematologic Malignancies Market Challenges
11.4 Hematologic Malignancies Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
